NEW YORK, Dec. 1, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company’s management team will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference. Canaccord Genuity New […]
Read MoreYou are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
